Publications. Cumulative Impact Factor: 168.1

Transkript

1 Publications Cumulative Impact Factor: Original Articles OA-1 Wenzel RR, Spieker LE, Su Q, Lüscher TF, Noll G (1998). Inhibition of muscle sympathetic nerve activity by moxonidine in patients with essential hypertension. Hypertension 32: Impact Factor: 5.6 OA-2 Spieker LE, Noll G, Lüscher TF (2000). Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistantly high triglyceride levels. J Cardiovasc Pharmacol 35: Impact Factor: 1.9 OA-3 Spieker LE, Noll G, Mitrovic V, Pacher R, Schulze M, Muntwyler J, Schalcher C, Kiowski W, Lüscher TF (2000). Acute hemodynamic and neurohumoral effects of selective ET A receptor blockade in patients with congestive heart failure. J Am Coll Cardiol 35: Impact Factor: 7.6 OA-4 Spieker LE, Corti R, Binggeli C, Lüscher TF, Noll G (2000). Baroreceptor dysfunction induced by nitric oxide synthase inhibition in man. J Am Coll Cardiol 36: Impact Factor: 7.6 OA-5 Binggeli C, Duru F, Corti R, Sudano I, Spieker LE, Turina A, Westermann P, Ostermeier M, Rahn M, Luscher TF, Noll G, Candinas R (2000). Autonomic nervous system-controlled cardiac pacing: a comparison between intracardiac impedance signal and muscle sympathetic nerve activity. Pacing Clin Electrophysiol 23: Impact Factor: 1.4 OA-6 Spieker LE, Sudano I, Hürlimann D, Lerch PG, Lang MG, Binggeli C, Ruschitzka F, Corti R, Lüscher TF, Noll G (2002). High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105: Impact Factor: 11.2 OA-7 Spieker LE, Hürlimann D, Ruschitzka F, Corti R, Enseleit F, Shaw S, Hayoz D, Deanfield JE, Lüscher TF, Noll G (2002). Mental stress induces prolonged endothelial dysfunction via endothelin A receptors. Circulation 105: Impact Factor: 11.2 OA-8 Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Béchir M, Spieker LE, Neidhart M, Michel BA, Gay RE, Lüscher TF, Gay S, Ruschitzka F (2002). Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106: Impact Factor: 11.2 OA-9 Corti R, Binggeli C, Sudano I, Spieker LE, Hänseler E, Ruschitzka F, Chaplin WF, Lüscher TF, Noll G (2002). Coffee acutely increases sympathetic nerve activity and blood pressure independently of caffeine content. Role of habitual versus nonhabitual drinking. Circulation 106: Impact Factor: 11.2 OA-10 Chenevard R, Hürlimann D, Béchir M, Enseleit F, Spieker LE, Hermann M, Riesen W, Gay S, Gay R, Neidhart M, Lüscher TF, Noll G, Ruschitzka F (2003). COX-2 inhibition improves endothelial function in patients with coronary artery disease. Circulation 107: Impact Factor: 11.2 OA-11 Binggeli C, Spieker LE, Corti R, Sudano I, Stojanovic V, Hayoz D, Lüscher TF, Noll G (2003). Statins enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients: A monitoring test of endothelial dysfunction for clinical practice? J Am Coll Cardiol 41:71-7. Impact Factor: 7.6 OA-12 Béchir M, Binggeli C, Corti R, Chenevard R, Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2003). Dysfunctional baroreflex regulation of sympathetic nerve activity in patients with vasovagal syncope. Circulation 107: Impact Factor: 11.2 OA-13 OA-14 Spieker LE, Lüscher TF, Noll G (2003). ET(A) receptors mediate vasoconstriction of large conduit arteries during reduced flow in man. J Cardiovasc Pharmacol 42; Impact Factor: 1.9 Spieker LE, Ruschitzka F, Badimon JJ, Noll G, Corti R (2004). Shear stress-dependent platelet function after LDL cholesterol apheresis. Thrombosis Research 113: Impact Factor: 1.7 OA-15 Hermann F, Forster A, Chenevard R, Enseleit F, Hurlimann D, Corti R, Spieker LE, Frey D, Hermann M, Riesen W, Neidhart M, Michel BA, Hellermann JP, Gay RE, Luscher TF, Gay S, Noll G, Ruschitzka F. (2005). Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 45: Impact Factor: 7.6 OA-16 Stojanovic V, Küng F, Spieker LE, Binggeli C, Sudano I, Hayoz D, Lüscher TF, Noll G (2005). Estrogens increase postischemic hyperemia in the skin microcirculation of healthy women. J Cardiovasc Pharmacol 45: Impact Factor: 1.9 OA-17 Hermann F, Spieker LE, Ruschitzka F, Sudano I, Hermann M, Binggeli C, Luscher TF, Riesen W, Noll G, Corti R (2006). Swiss dark chocolate improves endothelial and platelet function in smokers. Heart 92: Impact Factor: 3.2 OA-18 Sudano I, Spieker LE, Binggeli C, Ruschitzka F, Lüscher TF, Noll G, Corti R (2005). Coffee blunts mental

2 Publication List of Lukas Spieker August 29, 2006 Page 2 OA-19 OA-20 stress induced blood pressure increase in habitual but not in nonhabitual coffee drinkers. Hypertension 46: Impact Factor: 5.6 Flammer A, Spieker LE, Amacker N, Badimon JJ, Sasse B, Ruschitzka F, Noll G, Corti R (2006, In print). C-reactive protein influences shear stress-dependent platelet adhesion in patients with familiar hypercholesterolemia and coronary artery disease undergoing LDL apheresis. Thrombosis and Haemostasis. Impact Factor: 4.5 Maas R, Quitzau K, Schwedhelm E, Spieker LE, Rafflenbeul W, Steenpass A, Luscher TF, Boger RH (2006). Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. Atherosclerosis [Epub ahead of print] Impact Factor: 3.8 Cumulative Impact Factor (Original Articles): Review Articles and Editorials RA-1 Spieker LE, Binggeli C, Lüscher TF, Noll G (1997). Mitleid und Herzschmerz: Neues vom Sympathikus. Schweiz Med Wschrft 127: Impact Factor: 1.2 RA-2 Spieker LE, Lüscher TF, Noll G (2000). Das sympathische Nervensystem bei der arteriellen Hypertonie: Verbindung von Seele und Kreislauf? Medizinspiegel 3:7-12. Impact RA-3 Spieker LE, Noll G, Ruschitzka F, Maier W, Lüscher TF (2000). Working under pressure The endothelium in arterial hypertension. J Hum Hypertens 14: Impact Factor: 1.4 RA-4 Spieker LE, Lüscher TF, Noll G (2000). Homocystein als kardiovaskulärer Risikofaktor. Kardiovaskuläre Medizin 3: Impact RA-5 Corti R, Binggeli C, Sudano I, Spieker LE, Wenzel RR, Lüscher TF, Noll G (2000). The beauty and the beast: Aspects of the autonomic nervous system. News In Physiological Sciences 15: Impact Factor: 3.7 RA-6 Spieker LE, Noll G, Lüscher TF (2001). Therapeutic potential of endothelin receptor antagonists in cardiovascular disorders. Am J Cardiovasc Drugs 1; Impact RA-7 Spieker LE, Noll G, Ruschitzka F, Lüscher TF (2001). Endothelin receptor antagonists in congestive heart failure Blocking the beast while leaving the beauty untouched? Heart Fail Rev 6: Impact RA-8 Spieker LE, Lüscher TF, Noll G (2001). Beyond traditional risk factors: Homocystein and atherosclerosis. Heartdrug 1: Impact RA-9 Spieker LE, Lüscher TF, Noll G (2001). Current strategies and perspectives for correcting endothelial dysfunction in atherosclerosis. J Cardiovasc Pharmacol. 38(Suppl 2):S Impact Factor: 1.9 RA-10 Lüscher TF, Spieker LE, Noll G, Cosentino F (2001). Vascular effects of newer cardiovascular drugs: Focus on nebivolol and ACE-inhibitors. J Cardiovasc Pharmacol. 38(Suppl 3):S3-11. Impact Factor: 1.9 RA-11 Spieker LE, Noll G, Ruschitzka F, Lüscher TF (2001). Endothelin receptor antagonists in congestive heart failure A new therapeutic principle for the future? J Am Coll Cardiol 37: Impact Factor: 7.6 RA-12 Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2001). Die Diagnose der Herzinsuffizienz. Therapiewoche 17: Impact RA-13 Spieker LE, Lüscher TF (2001). Kardiovaskuläre Prävention kulinarisch oder klinisch? Kardiovaskuläre Medizin 4: Impact RA-14 Spieker LE, Eberli FR, Buser P, Mach F, Beer J, Urban P, Noll G, Rickenbacher P, Pfisterer M, Meier B, Lüscher TF (2002). Plättchenhemmung durch Thienopyridine beim akuten Koronarsyndrom praktische Empfehlungen aufgrund der CURE Studie. Kardiovaskuläre Medizin 5: Impact RA-15 Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2002). The management of hyperuricemia and gout in patients with congestive heart failure. European J Heart Failure 4: Impact Factor: 2.9 RA-16 Spieker LE, Lüscher TF (2003). Will endothelin receptor antagonists have a role in heart failure? Med Clin N Am 87: Impact Factor: 1.6 RA-17 Spieker LE, Lüscher TF (2003). Endothelin receptor antagonists in heart failure A refutation of a bold conjecture? European Journal of Heart Failure 5; Impact Factor: 2.9 RA-18 Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2003). Medikamentöse Therapie der Herzinsuffizienz. Cardiovasc 3; Impact RA-19 Spieker LE, Corti R, Hellermann JP, Eberli FR, Noll G, Lüscher TF. (2003) Niedermolekulare Heparine

3 Publication List of Lukas Spieker August 29, 2006 Page 3 beim akuten Koronarsyndrom Ist Enoxaparin überlegen? Kardiovaskuläre Medizin 6: Impact RA-20 Spieker LE, Noll G (2003). Pathophysiologische Herz-Kreislaufveränderungen bei Stress und Depression. Therapeutische Umschau 60: Impact RA-21 Spieker LE, Ruschitzka F, Noll G (2003). HDL-Cholesterin bei Atherosklerose Zuwenig des Guten. Schweizerisches Medizin Forum 39: Impact RA-22 Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2004). HDL and inflammation in atherosclerosis. Current Drug Target Immune, Endocrine and Metabolic Disorders 4: Impact RA-23 Corti R, Spieker LE, Mach F, Erne P, Moccetti T, Beer J, Urban P, Buser P, Rickenbacher P, Pfisterer M, Eberli FR, Bertel O, Meier B, Lüscher TF (2004). Plättchenhemmung durch Thienopyridine beim akuten Koronarsyndrom und nach perkutaner koronarer Intervention praktische Empfehlungen. Kardiovaskuläre Medizin 7; Impact RA-24 Spieker LE, Lüscher TF (2004). Die Rolle der Angiotensin II-Antagonisten in der antihypertensiven Pharmakotherapie. Ars Medici 12; Impact RA-25 Spieker LE (2004). Das Herz beim metabolischen Syndrom. Kardiovaskuläre Medizin 7: Impact RA-26 Spieker LE (2004). Vorhersage kardiovaskulärer Ereignisse: Endothelfunktion als Surrogatmarker. Cardiovasc 4;43. Impact RA-27 Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DJ (2005). Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 23: Impact Factor: 1.6 RA-28 Spieker LE, Stacchi R, Corti R, Noll G (2005). Der Cannabinoid-Rezeptor-Antagonist Rimonabant. Kardiovaskuläre Medizin 8; Impact RA-29 Sudano I, Binggeli C, Spieker LE, Lüscher TF, Ruschitzka F, Noll G, Corti R (2005). Cardiovascular effects of coffee: is it a risk factor? Prog Cardiovasc Nurs 20:65-9.Impact RA-29 Sudano I, Spieker LE, Corti R, Weber R, Lüscher TF (2006). Cardiovascular disease in HIV infection. Am Heart J 151: Impact Factor: 3.6 RA-30 Spieker LE, Noll G, Ruschitzka F, Lüscher TF (Submitted). The challenge of diagnosing heart failure. RA-31 Hollenberg NK, Schmitz H, Spieker LE, Lüscher TF, MacDonald I, Poulter N (In press). Dietary flavonoids and cardiovascular risk. British Journal of Cardiology. RA-32 Hermann F, Ruschitzka F, Spieker L, Sudano I, Noll G, Corti R (2005). The sweet secret of dark chocolate. Ther Umsch 62: Impact RA-33 Corti R, Sudano I, Spieker L, Binggeli C, Hermann F, Toenz D, Noll G (2005). Coffee poison or medicine? Ther Umsch 62: Impact RA-34 Sudano I, Spieker LE, Hermann F, Flammer A, Corti R, Noll G, Luscher TF (2006). Protection of endothelial function: targets for nutritional and pharmacological interventions. J Cardiovasc Pharmacol 47 Suppl 2:S Impact Factor: 1.9 Cumulative Impact Factor (Review Articles): 35.4 Case Reports CR-1 Spieker LE, Sütsch G (2003). Eine 22-jährige Frau mit akutem Myokardinfarkt. Kardiovaskuläre Medizin 6: Impact CR-2 Karadag B, Spieker LE, Schwitter J, Ruschitzka F, Noll G, Lüscher TF, Corti R (2004). Lyme carditis: restitutio ad integrum documented by cardiac MRI. Cardiology in Review 12: Impact CR-3 Spieker LE, Hufschmid U, Oechslin E, Jenni R (2004). Double aortic and pulmonary valves: an artifact generated by ultrasound refraction. J Am Soc Echocardiogr 17: Impact Factor: 1.4 CR-4 Spieker LE, Jenni R (2004). An apparently immobile mitral valve prosthesis leaflet. J Am Soc Echocardiogr 17;905. Impact Factor: 1.4 CR-5 Spieker LE, Maier W, Jenni R (2004). Eine Frau mit intramyokardialer Verkalkung. Kardiovaskuläre Medizin 7: Impact CR-6 Karadag B, Spieker LE, Wildermut S, Maier W, Böhm T, Lüscher TF, Corti R (2005). Sudden death in a

4 Publication List of Lukas Spieker August 29, 2006 Page 4 CR-7 CR-8 CR-9 soccer player: A unique case of anomalous coronary origin detected by 16-slice computed tomography imaging. Heart and Vessels 20: Impact Factor: 0.4 Spieker LE, Karadag B, Binggeli C, Corti R (2005). Rapid progression of atherosclerotic coronary artery disease in patients with HIV infection. Heart and Vessels 20; Impact Factor: 0.4 Spieker LE, Corti R, Noll G (2005). Eine Frau mit Bradykardie und Schwäche. Schweiz Med Forum 5;60-2. Impact Spieker LE, Burger P, Ritschard T, Noti C, Corti R (In print). Ein gebrochenes Herz nach einem Streit mit der Schwiegermutter: die Stress-induzierte Kardiomyopathie. Kardiovaskuläre Medizin. Impact Cumulative Impact Factor (Case Reports): 3.6 Book Chapters B-1 Spieker LE, Noll G, Ruschitzka F, Maier W, Lüscher TF. Endothelial function in hypertension. In: Schwartz CJ, Born GVR (Eds). Occlusive arterial disease. The interfaces among dyslipidemia, hypertension and diabetes. Schattauer (2001). B-2 Spieker LE, Lüscher TF. Hypertension and blood vessels: from diagnosing vascular events to the assessment of endothelial dysfunction. In: Birkenhäger WH, Robertson JIS, Zanchetti A (Eds). Handbook of Hypertension, Vol. 22: Hypertension in the twentieth century. Elsevier (2004). B-3 Spieker LE, Lüscher TF. Target Organ Damage: Endothelium and Vessels. In: Distance-learning course: Clinical Hypertension (2004). B-4 Spieker LE, Lüscher TF. Endothelium in hypertension: Nitric oxide. In: Oparil S, Weber MA (Eds). Hypertension: A companion to Brenner and Rector s The Kidney, 2 nd Ed. Elsevier (2005). B-5 Spieker LE, Lüscher TF. Endothelium, vascular smooth muscle, perturbations of cell membranes and signal transduction in hypertension. In: Battegay E, Lip GYH, Bakris GL (Eds.). Hypertension: Principles and practice. Dekker (In press). B-6 Lüscher TF, Noll G, Spieker LE, Corti R, Pepine CJ. Coronary spasm and atherothrombosis. In: Fuster V, Nabel EG, Topol EJ (Eds). Atherothrombosis and coronary artery disease, 2 nd Ed. Lippincott Williams & Wilkins (2005). B-7 Spieker LE, Lüscher TF. Protection of endothelial function (2005). Handbook of experimental pharmacology Handb Exp Pharmacol 170: Invited Lectures and Presentations (Selection) P-1 European Society of Cardiology (ESC), Stockholm Variability of muscle sympathetic nerve activity, arterial blood pressure, and heart rate. P-2 Schweizerische Gesellschaft für Kardiologie (SGK), Interlaken Wirkung von NO-Synthese- Hemmung auf Hämodynamik und Sympathikus. P-3 Lipid-Symposium, Zürich Hyperhomocysteinämie: klinische Bedeutung und Therapie. P-4 6 th Endothelin-Meeting, Montreal Acute hemodynamic and neurohumoral effects of selective ET A receptor blockade in patients with congestive heart failure. P-5 European Society of Cardiology (ESC), Barcelona Effects of NO synthase inhibition on muscle sympathetic nerve activity and hemodynamics in man. P-6 American Heart Association (AHA), New Orleans High-density lipoprotein restores endothelial function in hypercholesterolemic men. P-7 American College of Cardiology (ACC), Anaheim Baroreceptor dysfunction induced by nitric oxide synthase inhibition in man. P-8 Lipid-Symposium, Zürich Stress und Endothelfunktion. P-9 European Society for Clinical Investigation (ESCI), Barcelona HDL restores endothelial function in hypercholesterolemic men. P-10 Schweizerische Gesellschaft für Kardiologie (SGK), Zürich Endothelin-1 mediates vasoconstriction of large conduit arteries during reduced flow via endothelin A receptors in man. P-11 Lipid-Symposium, Zürich Neue Cholesterinsenker. P-12 Evidence-based Cardiology, Feusisberg The patient with multiple risk factors. P-13 The Menarini Series on Atherosclerosis, Naples Pharmacological modulation of the endothelium

5 Publication List of Lukas Spieker August 29, 2006 Page 5 in cardiovascular disease. P-14 1 st International Meeting on ADMA as a Cardiovascular Risk Factor, Hamburg Pharmacotherapy of coronary endothelial dysfunction. P-15 Klinisch-wissenschaftliche Konferenz, USZ, Zürich HDL Protektive Wirkung über den Lipidstoffwechsel hinaus. P-16 American Heart Association (AHA), Chicago Mental stress induces prolonged endothelial dysfunction via endothelin A receptors. P-17 Zürich Angiotensin II-Rezeptor Antagonisten in der Prävention kardiovaskulärer Endorgan- Schäden. P-18 Herzkreislauftag, Zürich Klinische Entscheidungen bei multimorbiden Herzpatienten. P-19 Zürich Duale Cholesterintherapie mit Ezetimibe und Statinen. P-20 American College of Cardiology (ACC), Chicago Marked coronary endothelial dysfunction in patients with low HDL and elevated C-reactive protein. P-21 Schweizerische Gesellschaft für Kardiologie, Lausanne AIDS eine kardiovaskuläre Krankheit? P-22 Hellenic Cardiology Society, Santorini Inflammation and atheroslerosis Does the endothelium provide a link? P-23 Zürich Arterielle Hypertonie Optimaler medikamentöser Endorganschutz. P-24 Schweizerische Gesellschaft für Innere Medizin Pathophysiologie der Herz-Kreislaufveränderungen bei Depression und Stress. P-25 Aging Forum, Bad Aibling Mental stress and atherosclerosis. P-26 Tag der offenen Tür, Kardiologie USZ Wie bleibt mein Herz gesund? P-27 6th Winter Meeting, Working Group on Heart Failure, Swiss Cardiology Society, Mürren Heart failure therapy in post-mi and DCM patients: Two pairs of shoes? P-28 Zürich Cholesterintherapie wie weiter? P-29 Controversies in Cardiology, Bern Erectile Dysfunction an unsolved problem. P-30 Schweizerische Gesellschaft für Kardiologie, Basel Metabolic syndrome the cardiologists view. P-31 Evidence-based Cardiology, Feusisberg The patient with multiple risk factors. P-32 Evidence-based Cardiology, Feusisberg Treatment of acute coronary syndrome. P-33 Symposium für Akutgeriatrie, Stadtspital Waid, Zürich Phosphodiesterasehemmer kein Problem im Alter. P-34 Herzkreislauf-Erkrankungen. Kurs für Pflegende. Universitätsstpital Zürich, 2004 und P-35 Fallvorstellung, Herzinsuffizienz-Update, Grenchen P-36 Herznotfall: aus der Sicht des Praktikers. HerzZentrum Bern, Bern 2006.